Lightchain Capital

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

SimpleRose Inc. is a technology company based in Saint Louis, Missouri, that specializes in developing a prescriptive analytics platform aimed at enhancing decision-making processes in complex environments. Founded in 2018, the company's solutions focus on optimizing operations through applications such as scheduling, production planning, and portfolio optimization. By leveraging algorithmic innovations for improved numerical accuracy and speed, SimpleRose enables organizations to tackle intricate operational challenges and make informed decisions in real-time.

SimpleRose Inc. is a technology company based in Saint Louis, Missouri, that specializes in developing a prescriptive analytics platform aimed at enhancing decision-making processes in complex environments. Founded in 2018, the company's solutions focus on optimizing operations through applications such as scheduling, production planning, and portfolio optimization. By leveraging algorithmic innovations for improved numerical accuracy and speed, SimpleRose enables organizations to tackle intricate operational challenges and make informed decisions in real-time.